481 related articles for article (PubMed ID: 29370152)
1. Recommendations of the Advisory Committee on Immunization Practices for Use of Herpes Zoster Vaccines.
Dooling KL; Guo A; Patel M; Lee GM; Moore K; Belongia EA; Harpaz R
MMWR Morb Mortal Wkly Rep; 2018 Jan; 67(3):103-108. PubMed ID: 29370152
[TBL] [Abstract][Full Text] [Related]
2. Use of Recombinant Zoster Vaccine in Immunocompromised Adults Aged ≥19 Years: Recommendations of the Advisory Committee on Immunization Practices - United States, 2022.
Anderson TC; Masters NB; Guo A; Shepersky L; Leidner AJ; Lee GM; Kotton CN; Dooling KL
MMWR Morb Mortal Wkly Rep; 2022 Jan; 71(3):80-84. PubMed ID: 35051134
[TBL] [Abstract][Full Text] [Related]
3. Update on recommendations for use of herpes zoster vaccine.
Hales CM; Harpaz R; Ortega-Sanchez I; Bialek SR;
MMWR Morb Mortal Wkly Rep; 2014 Aug; 63(33):729-31. PubMed ID: 25144544
[TBL] [Abstract][Full Text] [Related]
4. Update on the advisory committee on immunization practices' recommendations for use of herpes zoster vaccine.
Weaver BA;
J Am Osteopath Assoc; 2011 Oct; 111(10 Suppl 6):S31-3. PubMed ID: 22086893
[TBL] [Abstract][Full Text] [Related]
5. Incremental clinical and economic impact of recombinant zoster vaccination: real-world data in a budget impact model.
Patterson BJ; Herring WL; Van Oorschot D; Curran D; Carrico J; Zhang Y; Ackerson BK; Bruxvoort K; Sy LS; Tseng HF
J Manag Care Spec Pharm; 2020 Dec; 26(12):1567-1575. PubMed ID: 33043821
[TBL] [Abstract][Full Text] [Related]
6. Primary care physicians' experience with zoster vaccine live (ZVL) and awareness and attitudes regarding the new recombinant zoster vaccine (RZV).
Hurley LP; Allison MA; Dooling KL; O'Leary ST; Crane LA; Brtnikova M; Beaty BL; Allen JA; Guo A; Lindley MC; Kempe A
Vaccine; 2018 Nov; 36(48):7408-7414. PubMed ID: 30420121
[TBL] [Abstract][Full Text] [Related]
7. Comparative Antibody Responses to the Live-Attenuated and Recombinant Herpes Zoster Vaccines.
Schmid DS; Miao C; Leung J; Johnson M; Weinberg A; Levin MJ
J Virol; 2021 May; 95(12):. PubMed ID: 33762414
[TBL] [Abstract][Full Text] [Related]
8. Which patients should receive the herpes zoster vaccine?
Short MD; Fergus C
JAAPA; 2019 Sep; 32(9):18-20. PubMed ID: 31460969
[TBL] [Abstract][Full Text] [Related]
9. Efficacy, reactogenicity, and safety of the adjuvanted recombinant zoster vaccine for the prevention of herpes zoster in Chinese adults ≥ 50 years: A randomized, placebo-controlled trial.
Alexandra Echeverria Proano D; Zhu F; Sun X; Zoco J; Soni J; Parmar N; Ali SO;
Hum Vaccin Immunother; 2024 Dec; 20(1):2351584. PubMed ID: 38838170
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness of the Recommendations of the Advisory Committee on Immunization Practices for the Recombinant Adjuvanted Zoster Subunit Vaccine.
Le P; Rothberg MB
JAMA Intern Med; 2018 Sep; 178(9):1277-1278. PubMed ID: 29987323
[TBL] [Abstract][Full Text] [Related]
11. Vaccines for preventing herpes zoster in older adults.
Gagliardi AM; Andriolo BN; Torloni MR; Soares BG; de Oliveira Gomes J; Andriolo RB; Canteiro Cruz E
Cochrane Database Syst Rev; 2019 Nov; 2019(11):. PubMed ID: 31696946
[TBL] [Abstract][Full Text] [Related]
12. Shingrix: The New Adjuvanted Recombinant Herpes Zoster Vaccine.
James SF; Chahine EB; Sucher AJ; Hanna C
Ann Pharmacother; 2018 Jul; 52(7):673-680. PubMed ID: 29457489
[TBL] [Abstract][Full Text] [Related]
13. Postlicensure Safety Surveillance of Recombinant Zoster Vaccine (Shingrix) - United States, October 2017-June 2018.
Hesse EM; Shimabukuro TT; Su JR; Hibbs BF; Dooling KL; Goud R; Lewis P; Ng CS; Cano MV
MMWR Morb Mortal Wkly Rep; 2019 Feb; 68(4):91-94. PubMed ID: 30703077
[TBL] [Abstract][Full Text] [Related]
14. Update on herpes zoster vaccine: licensure for persons aged 50 through 59 years.
Centers for Disease Control and Prevention (CDC)
MMWR Morb Mortal Wkly Rep; 2011 Nov; 60(44):1528. PubMed ID: 22071592
[TBL] [Abstract][Full Text] [Related]
15. A practitioner's guide to the recombinant zoster vaccine: review of national vaccination recommendations.
Parikh R; Widenmaier R; Lecrenier N
Expert Rev Vaccines; 2021 Sep; 20(9):1065-1075. PubMed ID: 34311643
[TBL] [Abstract][Full Text] [Related]
16. Herpes Zoster Vaccines.
Harbecke R; Cohen JI; Oxman MN
J Infect Dis; 2021 Sep; 224(12 Suppl 2):S429-S442. PubMed ID: 34590136
[TBL] [Abstract][Full Text] [Related]
17. Shingrix--an adjuvanted, recombinant herpes zoster vaccine.
Med Lett Drugs Ther; 2017 Dec; 59(1535):195-196. PubMed ID: 29186082
[No Abstract] [Full Text] [Related]
18. Prevention of herpes zoster: recommendations of the Advisory Committee on Immunization Practices (ACIP).
Harpaz R; Ortega-Sanchez IR; Seward JF;
MMWR Recomm Rep; 2008 Jun; 57(RR-5):1-30; quiz CE2-4. PubMed ID: 18528318
[TBL] [Abstract][Full Text] [Related]
19. Immunogenicity, reactogenicity and safety of 2 doses of an adjuvanted herpes zoster subunit vaccine administered 2, 6 or 12 months apart in older adults: Results of a phase III, randomized, open-label, multicenter study.
Lal H; Poder A; Campora L; Geeraerts B; Oostvogels L; Vanden Abeele C; Heineman TC
Vaccine; 2018 Jan; 36(1):148-154. PubMed ID: 29174683
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Zoster Vaccine (Shingrix) to Prevent Herpes Zoster.
Sly JR; Harris AL
Nurs Womens Health; 2018 Oct; 22(5):417-422. PubMed ID: 30145235
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
